	US 11,851,677 B2
	Composition and methods for inducing myeloid suppressive cells and use thereof
Philippe A. Parone, San Diego, CA (US); Robert S. Tacke, San Diego, CA (US); Bahram Valamehr, San Diego, CA (US); Daniel Shoemaker, San Diego, CA (US); Martin Hosking, San Diego, CA (US); and Lisa Guerrettaz, San Diego, CA (US)
Assigned to Fate Therapeutics, Inc.
Appl. No. 16/622,237
Filed by FATE THERAPEUTICS, INC., San Diego, CA (US)
PCT Filed Jun. 13, 2018, PCT No. PCT/US2018/037286 § 371(c)(1), (2) Date Dec. 12, 2019, PCT Pub. No. WO2018/231951, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/519,123, filed on Jun. 13, 2017.
Prior Publication US 2020/0102536 A1, Apr. 2, 2020
Int. Cl. A61K 35/15 (2015.01); A61K 35/44 (2015.01); C12N 5/078 (2010.01)

CPC C12N 5/0634 (2013.01) [A61K 35/15 (2013.01); A61K 35/44 (2013.01); C12N 2500/02 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2311 (2013.01); C12N 2501/26 (2013.01); C12N 2501/727 (2013.01); C12N 2502/11 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2533/50 (2013.01)]

12 Claims

1. An in vitro method of generating a population of induced immune regulatory cells, comprising:

(i) obtaining induced definitive hemogenic endothelium cells (iHE); and

(ii) directing differentiation of iHE with a medium composition comprising a ROCK inhibitor, GMCSF, and MCSF;

thereby generating a population of induced immune regulatory cells comprising induced myeloid suppressive cells, wherein the induced myeloid suppressive cells are CD45⁺ and CD33⁺;

and wherein the cell population has enhanced therapeutic potential.